Global Hemophilia Market Size To Grow USD 17.8 Billion By 2030 | CAGR of 7.55%

Advertisement

The Global Hemophilia Market Size was valued at USD 12.1 billion in 2021 and the worldwide hemophilia market size is expected to reach USD 17.8 billion by 2030, According to a research report published by Spherical Insights & Consulting. Companies Covered: Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A, Medexus Pharmaceuticals Inc., Novo Nordisk A/S, octapharma ag, Pfizer Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceuticals Company ltd and among others.

New York, United States , March 14, 2023 (GLOBE NEWSWIRE) — The Global Hemophilia Market Size to grow from USD 12.1 billion in 2021 to USD 17.8 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 7.55% during the forecast period. The growth of the hemophilia treatment market share is driven by increase in the prevalence of hemophilia, technological advancements in the treatment of hemophilia, and favourable government initiatives for hemophilia management. according to the World Federation of Hemophilia October 2021 report, owing to the sex-linkage of the disorder, there is a bigger prominence in males than females. Hemophilia occurs worldwide and across all racial groups. North America Expected to Hold Significant Share in the Market and Expected to do Same Over the Forecast Period.   

Global Economy: Recession Risk Rising Analysis and Russia-Ukraine Conflict War Impact we have added in the final premium report.

Advertisement

Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1545  

A category of bleeding disorders known as haemophilia are characterised by slow blood clotting. It primarily falls under the categories of haemophilia A and haemophilia B. The absence of clotting factor VIII or IX in the blood is the root cause of it. Hemophilia is typically handed down through families (inherited). Children that are male tend to inherit it the most. Bleeding is the hallmark sign of haemophilia. Minor cases are anticipated to go unnoticed until significant bleeding after surgery or an injury. In severe cases, bleeding happens randomly. Anywhere can have internal bleeding, and bleeding into joints is frequent. After a person experiences an unusual bleeding event, it is diagnosed. If other family members are affected, a blood test can also be used to identify the issue. The main course of treatment involves injecting blood through a vein with extra clotting factor (intravenous infusions). If you suffer from this bleeding disorder, certain precautions must be followed during surgery. Therefore, the patient’s surgeon needs to be aware of this problem before performing. Sharing information about the disorder with blood relations is crucial because they might also develop the condition. The lack of therapeutic therapy choices and the increasing pressure on regulatory authorities to address it are driving up R&D activities. An organisation of people who operate in the construction sector is referred to as a “ecosystem.” The market share for haemophilia therapy has increased as a result of rising haemophilia prevalence, technological advancements in haemophilia treatment, and supportive governmental initiatives for haemophilia management. The high cost of haemophilia therapy, the dearth of haemophilia treatments, and the significant side effects associated with plasma-derived products are all expected to restrain the market’s growth.

Browse key industry insights spread across 210 pages with 122 market data tables and figures & charts from the reportGlobal Hemophilia Market Size, Share, and COVID-19 Impact Analysis, By Treatment (On-demand, Prophylaxis), By Therapy (Immune Tolerance Induction (ITI) Therapy, Replacement Therapy, Gene Therapy), By End Use (Hospital Pharmacies, Retail Pharmacy, Others), by Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030”.  in detail along with the table of contents.

Buy Now Full Report: https://www.sphericalinsights.com/checkout/1545  

The On Demand holds the largest market share over the forecast period.

On the basis of treatment, the hemophilia market is segmented into prophylaxis and on-demand treatment. Among these, the on demand holds the largest market share over the forecast period. On the other hand, propphylaxis segment is witnessing the fastest market growth over the forecast period. Prophylaxis, a well-established therapy that entails routinely giving clotting factor concentrates to those with severe haemophilia, is what is causing the condition’s rise in prevalence. The length of this treatment depends on how serious the patient’s condition is. Treatment for prophylaxis is anticipated to increase quality of life while lowering productivity loss.

The Replacement Therapy is dominating the market with the largest market share over the forecast period.

Based on the therapy, the hemophilia market is segmented into immune tolerance induction (ITI) therapy, replacement therapy, and gene therapy. Among these, the replacement therapy is dominating the market with the largest market share over the forecast period. The gold standard of treatment is replacement therapy, which helps patients replace their missing clotting factor. Gene therapy, which seeks out broken DNA bases and replaces them with functional ones, is one of the more recent areas. AMT-060, a potential drug developed by UniQure to treat type B, is presently undergoing clinical testing. The therapy aids patients in starting to produce factor IX once more by inserting a functioning copy of the factor IX gene into the liver cells of type B patients.

Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/1545  

The Hospital segment is dominating the market with the largest market share over the forecast period.

On the basis of end user, the hemophilia market is segmented into hospital pharmacies, retail pharmacy, and others. Among these, the hospital segment is dominating the market with the largest market share over the forecast period. The hospital market is driven by the potential for board certification for experienced hemologists, the relevance of offering top-notch treatment programmes, and the productivity gains they bring about. To assist both patients and insurance companies, these healthcare institutions offer treatments at fair prices. Because new medications are now so easily accessible, hospitals are now more likely to treat bleeding disorders. In-depth hospital treatment planning and continuing supervision are also expected to increase patient choice for these drug healthcare facilities. This inherited bleeding disorder is resulting in a rise in hospital admissions. The demand for improved treatment is projected to encourage product uptake in these facilities.

North America is dominating the market with the largest market share over the forecast period.

Among all other regions, the North America is dominating the market with the largest market share over the forecast period. Initial regional development drivers include rising prevalence and a rising propensity for preventative medicine, according to predictions. In the US, this condition is discovered quite early in life. On the other hand, Asia-Pacific is anticipated to see the most increase during the anticipated time. Increased per capita use of medications for factor VIII and IX insufficiency and early identification of the illnesses in countries like Japan, India, Indonesia, and Malaysia are key impact-producing variables.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Companies Covered: Bayer AG, CSL Ltd. (CSL Behring), F. Hoffmann-La Roche AG, Grifols, S.A, Medexus Pharmaceuticals Inc., Novo Nordisk A/S, octapharma ag, Pfizer Inc., Swedish Orphan Biovitrum AB, Takeda Pharmaceuticals Company ltd and among others.  

Get Discount At @ https://www.sphericalinsights.com/request-discount/1545  

Browse Related Reports

Global Forensic Imaging Market Size, Share, Trends, Industry Analysis Report, By Modality (X-ray, CT, MRI, Ultrasound); By Application (Death Investigations, Clinical Studies); By End-Use (Forensic Institutes, Hospitals, Others); By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030

https://www.sphericalinsights.com/reports/forensic-imaging-market

Global Aortic Valve Replacement Devices Market Size, Share, Trends Analysis, COVID-19 Impact Analysis Report, By Surgery (Open, Minimally Invasive), By Product (Transcatheter Aortic Valve, Sutureless Valve), By End-user, And Analysis and Forecast 2021 – 2030.

https://www.sphericalinsights.com/reports/aortic-valve-replacement-devices-market

Global Biologics Market Size, Share & Trends Analysis Report, COVID-19 Impact Analysis Report, By Source (Microbial, Mammalian), By Products (Monoclonal Antibodies, Vaccines, Recombinant Proteins, Antisense, RNAi), By Disease Category, By Manufacturing, And, By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis, and Forecast till 2030.

https://www.sphericalinsights.com/reports/biologics-market 

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company’s mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: [email protected], [email protected]

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. AfternoonHeadlines.com takes no editorial responsibility for the same.